|
WO2021062157A1
|
|
Compositions and methods for treating metastatic gastrointestinal cancer
|
|
WO2021050954A1
|
|
Compositions and methods related to human neutralizing antibodies to hepatitis b
|
|
WO2021050563A1
|
|
Antibody treatment for lesional tissue of hidradenitis suppurativa
|
|
WO2021041397A2
|
|
Compositions and methods for identifying gene clusters
|
|
WO2021034913A1
|
|
Engineering ph-dependent antigen binding activity into anti-hiv antibodies with improved pharmacokinetics
|
|
WO2021030735A1
|
|
Crispr genome editing with cell surface display to produce homozygously edited eukaryotic cells
|
|
US2021045387A1
|
|
Compositions and methods to inhibit arthropod host-seeking behavior
|
|
US2021024889A1
|
|
Antibody gene editing in b lymphocytes
|
|
WO2021016433A1
|
|
Antibacterial compounds, compositions thereof, and methods using same
|
|
WO2020257756A1
|
|
Self-organizing neural ectodermal lineage cellular structures, and compositions and methods relating thereto
|
|
WO2020247599A1
|
|
4-substituted pyrano[3,4,b]pyrazine kappa agonists for treating drug dependency
|
|
WO2020251834A1
|
|
Antibodies and methods for treatment of viral infections
|
|
WO2020247569A1
|
|
Methods of treating human fulminant viral hepatitis
|
|
WO2020237115A1
|
|
Methods of full-length rna profiling
|
|
WO2020215055A1
|
|
Unraveling receptor-metabolite interactions in the human microbiome
|
|
WO2020176846A2
|
|
Apoe genotyping in cancer prognostics and treatment
|
|
WO2020172406A1
|
|
Modified microorganisms expressing saga and related compositions for immunomodulation against infection and cancer immunotherapy
|
|
WO2020167566A1
|
|
Methods and compositions for the treatment of alcohol use disorders
|
|
WO2020160229A1
|
|
Hybrid multi-photon microscopy
|
|
WO2020154363A1
|
|
Engineered nucleobindin1-immunoglobulin fusion protein
|
